By contrast, pancreatic neuroendocrine tumors (PNETs), generally do not harbor TP53 mutations, exhibit only minimal deletions of CDKN2A61, and have a 5 year survival rate of >50% when treated with apoptosis-inducing therapy62. This evidence concerns the gene TP53 and pancreatic neuroendocrine tumor.